Formulations for treatment of adipose tissue, cutaneous tissue and disorders, and muscular tissue
OwnerJohn Daniel Dobakinventor
Life of this patent
Estimating the term…
Abstract
Compositions, formulations, methods, and systems for treating regional fat deposits and fat-related conditions, dermal conditions, and muscular conditions. Methods comprise administering a composition comprising at least one compound that reduces desensitization of beta adrenergic receptors, for example a glucocorticosteroid, and/or at least one long-acting beta-2 adrenergic receptor agonist, for example, formoterol. Compositions to be administered include sustained release formulations comprising at least one long-acting beta-2 adrenergic receptor agonist, at least one compound that reduces desensitization of beta adrenergic receptors, or both in a sustained crystalline microparticle form.
Claims42
A method for reducing a regional fat deposit in a subject in need thereof comprising administering to the subject, a sustained release pharmaceutical composition comprising a therapeutically effective amount of at least one compound for reducing desensitization of beta adrenergic receptors wherein the regional fat deposit in the subject is reduced.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for reducing a regional fat deposit in a subject in need thereof comprising administering to the subject:
- (a) a therapeutically effective amount of one or more adrenergic receptor pathway-stimulating compounds;
- and
- (b) a therapeutically effective amount of at least one compound for reducing beta adrenergic receptor desensitization.
(canceled)
(canceled)
(canceled)
(canceled)
A sustained release pharmaceutical composition comprising a therapeutically effective amount of at least one compound for reducing desensitization of beta adrenergic receptors, wherein the therapeutically effective amount of the at least one compound comprises a crystalline microparticle suspension of the at least one compound and wherein the composition provides a sustained release form.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.